Banning DTC Rx ads will not lower drug prices, says US Budget Office
This article was originally published in SRA
Banning direct-to-consumer advertising for new prescription medicines in the US is unlikely to help reduce consumer spending on drugs and could result in drug makers changing their marketing strategy by spending more on promoting their products to physicians, the Congressional Budget Office has stated in an issue brief1.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.